Edwards' chance for fresh blood as CFO retires
This article was originally published in Clinica
Executive Summary
On the same day that stuttering heart valve specialist Edwards Lifesciences announced a $750 million share repurchase program in a bid to placate shareholders, its CFO said he would retire later this year. The departure of Thomas Abate, who has been at the company for 31 years and turns 60 in August, is “a bit surprising but understandable given recent misses and related stock performance”, said Jefferies analyst Raj Denhoy. It could even be a positive, giving Edwards chance to bring in fresh blood after a difficult period.